News
Der Pharmakonzern Roche hat einen Rückschlag in einer Phase-III-Studie erlitten. Es geht um das Blutkrebs-Medikament ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback